Proteomic Profile of Ischemic Heart Disease in Heart Failure скачать в хорошем качестве

Proteomic Profile of Ischemic Heart Disease in Heart Failure

Kayode O. Kuku, MD, a Post-doctoral Fellow at the Heart Disease Phenomics Laboratory, for the National Institutes of Health in Bethesda, MD, breaks down the discoveries made in his article appearing in the July 2025, issue of Mayo Clinic Proceedings, where looking at a heart failure community cohort enrolled between September 10, 2003, to September 18, 2012, with linked medical records and measured 7289 plasma protein targets using an aptamer-based assay, ischemic heart disease, defined by prior myocardial infarction, angiographic coronary disease, or revascularization, and using a cause-specific hazards model to test the association between ischemic heart disease status and cardiovascular mortality while considering the interaction by ejection fraction group, to evaluate the cross-sectional association of proteins with ischemic heart disease status and with cardiovascular risk factors, he found an unmet need in heart failure phenotyping. Using high throughput proteomics, he and his colleagues identified distinct plasma protein profiles and novel biomarkers associated with ischemic heart disease. He notes these findings emphasize the significant and prognostic role of ischemic heart disease, underscored by distinct biological signatures potentially relevant to heart failure management and phenotyping. Available at: https://mayocl.in/4kl5r9q